EMEND IV In Salvage Treatment of Chemotherapy-Induced Vomiting.

Trial Profile

EMEND IV In Salvage Treatment of Chemotherapy-Induced Vomiting.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 23 Mar 2017

At a glance

  • Drugs Fosaprepitant (Primary) ; Dexamethasone; Serotonin 3 receptor modulators
  • Indications Chemotherapy-induced nausea and vomiting
  • Focus Therapeutic Use
  • Acronyms EVADE
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 28 Oct 2014 Status changed from completed to discontinued as reported by ClinicalTrials.gov record.
    • 23 Jan 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
    • 12 Jul 2013 Planned end date changed from 1 Jul 2013 to 1 Jan 2014 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top